Bio-Rad Laboratories Q4 2023 Adj EPS $3.10 Beats $2.82 Estimate, Sales $681.20M Miss $685.09M Estimate
Portfolio Pulse from Benzinga Newsdesk
Bio-Rad Laboratories (NYSE:BIO) reported Q4 2023 adjusted EPS of $3.10, surpassing the $2.82 estimate, but its sales of $681.20M fell short of the $685.09M estimate, marking a 6.72% decrease from the previous year.
February 15, 2024 | 9:16 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bio-Rad Laboratories reported higher-than-expected Q4 2023 EPS but missed sales estimates, with a year-over-year decrease.
While the EPS beat may positively impact investor sentiment towards Bio-Rad Laboratories, the miss on sales estimates and the year-over-year decrease could temper any potential stock price gains. The mixed results present a neutral outlook in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100